J Clin Neurol.  2017 Apr;13(2):209-211. 10.3988/jcn.2017.13.2.209.

Reversible Corpus Callosal Lesions Associated with the Use of Adalimumab for Ulcerative Colitis

• Park JW
• Seok HY
• Kim Y
• Kim BJ

• KMID: 2376028
• DOI: http://doi.org/10.3988/jcn.2017.13.2.209

Abstract

No abstract available.

MeSH Terms

Adalimumab*
Colitis, Ulcerative*
Ulcer*
Adalimumab

Figure

• 

  Fig. 1 Diffusion-weighted imaging revealed an ovoid-shaped lesion with restricted diffusion in the corpus callosum and splenium on the day of admission (A and B). Follow-up FLAIR and T2-weighted images (C-E) showed only a subtle remnant of the lesion in the splenium (white arrows). There was no enhancement of the lesion on gadolinium-enhanced T1-weighted images. FLAIR: fluid attenuated inversion recovery.

Reference

1. Liu WM, Lin CH. A reversible stroke-like splenial lesion in viral encephalopathy. Acta Neurol Taiwan. 2013; 22:117–121.

2. Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A, et al. Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med. 2013; 2013:671935.

3. Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol. 2004; 190:446–455.

4. Bellesi M, Logullo F, Di Bella P, Provinciali L. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol. 2006; 253:668–669.

5. Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet. 2015; 54:1107–1123.

6. Ali F, Laughlin RS. Asymptomatic CNS demyelination related to TNF-α inhibitor therapy. Neurol Neuroimmunol Neuroinflamm. 2016; 4:e298.